{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-226123","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2022-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.911732+00:00","generated_at":"2026-06-23T22:10:11.765458+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva completes acquisition of La Jolla Pharmaceutical for $6.23 per share","bullets":["Tender offer accepted 21,703,224 shares (~87.03% of outstanding) at $6.23 per share, no interest.","Merger completed on August 22, 2022, with La Jolla surviving as wholly-owned subsidiary.","All outstanding shares (other than Innoviva-Owned and La Jolla-Owned) converted to $6.23 cash per share.","Series C-1 Preferred Shares converted to cash equal to 1,724.04 times the Merger Consideration.","Options with exercise price below $6.23 received cash for spread; options at or above $6.23 cancelled for no consideration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-226123","json":"https://secwatch.observer/filing/0001193125-22-226123.json","markdown":"https://secwatch.observer/filing/0001193125-22-226123.md","text":"https://secwatch.observer/filing/0001193125-22-226123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000119312522226123/0001193125-22-226123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000119312522226123/d233621d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T22:10:11.765458+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}